Search results
Showing 811 to 825 of 1291 results for position
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued Reference number: GID-TA10539
Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.
Outside interests of the NICE board
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
This guide describes the process NICE uses to develop NICE quality standards
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
NICE's Freedom of Information Act 2000 provides a right of access to recorded information held by public authorities.
How we collect and use your personal information, and your rights under data protection legislation.
Day-to-day decision making is the responsibility of NICE's executive team.
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .